USFDA Voluntary Action Indicated Drives Supriya’s FY27 Growth Plan
Supriya Lifescience Limited — Q4 FY26 Earnings Conference Call (May 28, 2026) 1. Overall Tone of Management: Optimistic Management highlights multiple positives: “significant regulatory milestone” (USFDA EIR with “Voluntary Action Indicated”), “achieved our FY ’26 revenue…
